ReviewFrontiers in immunology2026
Deciphering the functions of NELL2 in tumorigenesis and beyond.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
NELL2, a neuron-specific secreted glycoprotein, has emerged as a key regulator in multiple physiological and pathological contexts, including neurodegeneration, immunity, reproduction and cancer. Despite its diverse roles, the context-dependent duality of NELL2-acting as both an oncogene and tumor suppressor, a neuroprotectant and contributor to hyperexcitability-remains mechanistically unclear. Moreover, the tissue-specific signaling cross-talk of NELL2 complicates its therapeutic targeting. Research on NELL2 holds transformative potential for precision medicine, offering insights into cancer therapy, neurodegenerative disease intervention, and infertility treatment, while highlighting the need for mechanistic clarity and context-specific strategies to realize its diagnostic and therapeutic promise. Here, we consolidated research advances of NELL2, delineating its structural features, regulatory networks, and context-dependent roles in neurodegeneration, immunity, reproduction and cancer. By highlighting unresolved mechanistic ambiguities and therapeutic translatability, our work helps to illuminate potential of NELL2 as a diagnostic marker and therapeutic target across diverse diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.